Laboratory of Neuro Imaging, Dept. of Neurology, UCLA School of Medicine, Los Angeles, CA, USA.
Dept. of Psychiatry, University of Illinois-Chicago, Chicago, IL, USA; Dept. of Bioengineering, University of Illinois-Chicago, Chicago, IL, USA; Community Psychiatry Associates, Sacramento, CA, USA.
Neuroimage. 2011 Jul 1;57(1):5-14. doi: 10.1016/j.neuroimage.2011.01.079. Epub 2011 Feb 23.
This paper responds to Thompson and Holland (2011), who challenged our tensor-based morphometry (TBM) method for estimating rates of brain changes in serial MRI from 431 subjects scanned every 6 months, for 2 years. Thompson and Holland noted an unexplained jump in our atrophy rate estimates: an offset between 0 and 6 months that may bias clinical trial power calculations. We identified why this jump occurs and propose a solution. By enforcing inverse-consistency in our TBM method, the offset dropped from 1.4% to 0.28%, giving plausible anatomical trajectories. Transitivity error accounted for the minimal remaining offset. Drug trial sample size estimates with the revised TBM-derived metrics are highly competitive with other methods, though higher than previously reported sample size estimates by a factor of 1.6 to 2.4. Importantly, estimates are far below those given in the critique. To demonstrate a 25% slowing of atrophic rates with 80% power, 62 AD and 129 MCI subjects would be required for a 2-year trial, and 91 AD and 192 MCI subjects for a 1-year trial.
本文回应了 Thompson 和 Holland(2011)的观点,他们对我们的基于张量的形态计量学(TBM)方法提出了质疑,该方法用于估计 431 名受试者在 2 年内每 6 个月进行一次的连续 MRI 中大脑变化的速率。Thompson 和 Holland 注意到我们的萎缩率估计值中出现了一个无法解释的跳跃:0 到 6 个月之间的一个偏移量,可能会影响临床试验的效力计算。我们确定了这种跳跃发生的原因,并提出了一个解决方案。通过在我们的 TBM 方法中强制实施反一致性,偏移量从 1.4%降至 0.28%,给出了合理的解剖轨迹。传递误差解释了最小的剩余偏移量。使用经过修订的 TBM 衍生指标进行药物试验的样本量估计与其他方法非常有竞争力,尽管比以前报告的样本量估计值高 1.6 到 2.4 倍。重要的是,估计值远低于评论中的值。为了在 80%的效力下证明萎缩率降低 25%,需要 62 名 AD 和 129 名 MCI 受试者进行为期 2 年的试验,需要 91 名 AD 和 192 名 MCI 受试者进行为期 1 年的试验。